oncbrain — oncology meeting digest

NRG Oncology RTOG 0539

Tue, 09 Jun 2026 00:00:00 GMT

[Early signal] 10-yr PFS 85.2%, 72.2%, 42.5% for low/intermediate/high-risk meningioma with risk-adapted observation or RT (median f/u ~12yr). Eligible: WHO grade 1-3 meningioma, post-resection (GTR or STR), newly-diagnosed or recurr

RAPCHEM (BOOG 2010-03)

Tue, 09 Jun 2026 00:00:00 GMT

[Early signal] 10-yr locoregional recurrence 2.9% overall with risk-stratified RT de-escalation after NAC + surgery in cN1 breast cancer. Eligible: Breast cancer cT<5cm cN1-3, receiving NAC prior to BCS or mastectomy

mRCAT-III

Tue, 02 Jun 2026 00:00:00 GMT

[Early signal] pCR 61% vs 29% (p<0.0001) with node-sparing SCRT + CAPOX + tislelizumab vs conventional SCRT + CAPOX in pMMR LARC. Eligible: pMMR/MSS LARC, cT3-4N0/+M0, tumor ≤10cm from anal verge, no positive lateral LN

ctDNA surveillance in non-operative rectal cancer management

Mon, 01 Jun 2026 00:00:00 GMT

[Early signal] ctDNA sensitivity only 41% for local regrowth vs 74% for distant mets in 110 NOM rectal pts; risk stratifies but cannot replace imaging. Eligible: Stage I-III MSS rectal, cCR/nCR after NAT, undergoing NOM

CAN-2409

Sun, 31 May 2026 00:00:00 GMT

[Early signal] DFS HR 0.70 vs placebo (p=0.0155), driven by 2yr biopsy pCR 80.4% vs 63.6%; OS/PCSM immature at 50.3mo. Eligible: High/intermediate-risk localized prostate cancer, RT 78Gy

MIRACLE-2

Sun, 31 May 2026 00:00:00 GMT

[Early signal] 68% ORR, median OS 23.2mo, 18% NED in MSS unresectable metastatic rectal ca (N=50). Eligible: MSS unresectable metastatic rectal cancer, synchronous mets, first-line

RAD-IO

Sat, 30 May 2026 00:00:00 GMT

[Early signal] 12-month DFS 80% (40/50; 95% CI 0.67-0.89) with durvalumab + chemoRT in MIBC, clearing GO threshold ≥75%; single-arm. Eligible: MIBC cT2-T3, 13% node-positive, 75% prior neoadjuvant chemo, median age 69

MIBC Management Post-pCR / Bladder-Sparing Session

Sat, 30 May 2026 00:00:00 GMT

[Early signal] Durvalumab + CRT (55 Gy/20 fr) feasible in 54 MIBC (87% full RT); pCR after NAC carries 85% 5-yr OS per SWOG 8710. Eligible: MIBC (cT2-4a N0), curative-intent bladder-sparing candidates

NRG Clinico-Transcriptomic Risk Stratification (Abstract 5000)

Sat, 30 May 2026 00:00:00 GMT

[Early signal] 22-gene GC independently predicts MFS, DM, and OS; combined NRG score reclassifies ~25% discordant NCCN high-risk pts for AAP intensification. Eligible: NCCN ≥ high-risk localized prostate cancer, RT+ADT candidates

A-DREAM (ALLIANCE mAPMS)

Sat, 30 May 2026 00:00:00 GMT

[Early signal] ADT+ARPI interruption in mHSPC: 41% treatment-free with eugonadal T at 18mo (1° EP); 38.5% still off-tx at 26.9mo FU. Eligible: mHSPC achieving PSA<0.2 after ≥18-24mo ADT+ARPI, low-volume predominant

CHRYSALIS-2 (1L Ami+Laz, Atypical EGFR+)

Sat, 30 May 2026 00:00:00 GMT

[Early signal] Median OS 41.0 mo (95% CI 27.7-NE) with ami+laz in 1L atypical EGFR+ advanced NSCLC; single-arm, n=49. Eligible: Advanced NSCLC, atypical EGFR mutation, treatment-naive

PEACE V–STORM

Fri, 22 May 2026 00:00:00 GMT

[Early signal] 4-yr MFS 76% (ENRT) vs 63% (MDT), HR 0.62 favoring elective nodal RT for PET+ pelvic nodal prostate oligorecurrence. Eligible: Pelvic nodal oligorecurrence (≤5 PET+ nodes), prostate, post-radical tx, PS 0-1

Bladder Adjuvant Radiotherapy

Thu, 21 May 2026 00:00:00 GMT

[Early signal] 2-yr LRFS 87.1% vs 76.0% (HR 0.43, p=0.04) favoring adj pelvic IMRT post-cystectomy in high-risk MIBC; DFS/OS NS. Eligible: High-risk urothelial MIBC post-RC (pT3-4, pN+, margin+, or ≤10 nodes), periopera

Single-fraction SABR for primary NSCLC and pulmonary oligometastases (pooled analysis, n=1687)

Tue, 19 May 2026 00:00:00 GMT

[Early signal] 2yr LC 90-93%, G3+ AEs 2.9% across 1687 pts treated with SF-SABR at 3 institutions. Eligible: Inoperable primary NSCLC or pulmonary oligomets, multi-institution pooled cohort

HEAT Trial

Mon, 18 May 2026 00:00:00 GMT

[Early signal] SBRT 5 fx non-inferior to EHRT for BF (7% vs 7.4%, p-noninferiority=0.007 at 4.25y) in low-int risk PCa; interim data. Eligible: Low-intermediate risk localized PCa, IPSS <12, ADT-eligible

INRT-AIR & DARTBOARD (ENI omission, HNSCC)

Mon, 18 May 2026 00:00:00 GMT

[Early signal] 5-yr solitary ENI recurrence 0% in 117 HNSCC pts on AI-assisted INRT omitting elective nodal fields. Eligible: HNSCC oropharynx/larynx/hypopharynx, stage I-IVB, definitive CRT candidates

FASTRACK II (TROG 15.03)

Mon, 18 May 2026 00:00:00 GMT

[Early signal] 100% LC at 84 months in primary RCC (N=70) treated with SABR; G3 AE 10%, no grade 4 events or cancer deaths. Eligible: Inoperable/surgery-declining primary RCC, T1b-dominant, median age 77

OLIGOMA

Sun, 17 May 2026 00:00:00 GMT

[Early signal] mPFS 35.8 vs 20.4 mo, HR 0.48; first RCT positive for MDT in oligometastatic breast cancer. Eligible: Metastatic breast, ≤5 mets, any systemic therapy line

Dutch BCRG Breast Boost (Modern Systemic Era)

Sun, 17 May 2026 00:00:00 GMT

[Early signal] 10-yr IBTR 1.2% with or without boost in 0-2 risk-factor BCT pts; boost omission appears safe in modern systemic era. Eligible: Early-stage breast cancer, BCT + WBRT, modern systemic therapy era, stratified b

RAPCHEM

Sun, 17 May 2026 00:00:00 GMT

[Early signal] 10yr locoregional recurrence <3% with nodal-response-guided RT de-escalation after neoadjuvant in breast cancer. Eligible: Node-positive breast cancer achieving pathological nodal response after neoadjuv

OligoCare

Sun, 17 May 2026 00:00:00 GMT

[Early signal] 88.6% local control at 3yrs across 2447 pts; CRC shows worst local control despite highest delivered dose. Eligible: Oligometastatic solid tumors, multiple histologies, 1-5 mets, SABR-eligible

EXTEND

Sun, 17 May 2026 00:00:00 GMT

[Early signal] Phase II RCT of MDT added to SOC for oligometastatic solid tumors, all histology baskets; no effect size in source tweet. Eligible: Oligometastatic solid tumors, multiple histologies, all disease sites, systemic

PRIME

Sun, 17 May 2026 00:00:00 GMT

[Early signal] SBRT 5fx with pelvic RT: G3+ toxicity <1%, comparable early BFFS to moderate hypo (N~434); mature 4-5yr endpoint pending. Eligible: High-risk, very high-risk, or node-positive non-metastatic prostate cancer

PIVOTALboost

Sun, 17 May 2026 00:00:00 GMT

[Early signal] Late G2+ bowel 6.5-8.7%, bladder 16.5-24.1% at 2yr, no increase with focal boost or pelvic node RT vs prostate-only (N=1465). Eligible: High-risk localised prostate cancer, moderately fractionated 20-fraction RT

PACE-NODES

Sun, 17 May 2026 00:00:00 GMT

[Early signal] PPN-SBRT increases G≥2 GI toxicity (28% vs 21%) vs prostate-only SBRT; symptoms resolved by 12wk; GU toxicity equivalent; efficacy endpoint pending. Eligible: High-risk localised prostate (T3a-T4, Gleason 8-10, or PSA >20), planned ADT 12-

PEACE-2

Sun, 17 May 2026 00:00:00 GMT

[Early signal] Pelvic RT adds no significant cPFS benefit over prostate-only RT in very high-risk PCa with 3yr ADT (HR 0.81, p=0.088) at interim analysis. Eligible: Very high-risk localized prostate Ca (≥2 of Gleason ≥8, T3-T4, PSA ≥20), N0M0

RCC SBRT 5-year LC

Sun, 17 May 2026 00:00:00 GMT

[Early signal] 100% 5-yr local control for RCC treated with SBRT; no additional endpoints in source.